GlassScriptPhysician profile
Corey D Finch
NPI 1407903644
$4,389.32
in general payments reported to CMS, 2019-2025
40 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $176 · 2021: $857 · 2022: $791 · 2023: $992 · 2024: $435 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,905 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.36 |
| Education | $117.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $940.00 | 2019-2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $380.93 | 2019-2025 | Cobenfy |
| Lilly USA, LLC | $249.64 | 2020-2023 | Trulicity, Basaglar, Humalog |
| Corium, LLC | $223.15 | 2022-2023 | Azstarys, Adlarity |
| Sunovion Pharmaceuticals INC. | $217.64 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $195.71 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $188.86 | 2020-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $185.27 | 2019-2022 | |
| Abbvie INC. | $151.79 | 2021-2023 | |
| Sk Life Science, INC. | $150.80 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $136.24 | 2025 | |
| Astellas Pharma US INC | $136.00 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $131.58 | 2023 | Gemtesa, Aptiom |
| Bayer Healthcare Pharmaceuticals INC. | $130.27 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $92.14 | 2020-2024 | Airsupra |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Finch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.